Lilly(Eli) & Company
Research Lilly(Eli) & Company (LLY) on Bullrun: valuation model: 18.9% overvalued, market cap USD 1.16T, P/E 41.9, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLLY
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal18.9% overvalued
- Market capUSD 1.16T
- P/E41.9
- Dividend yield0.6%
- Financial periodQ2 2026
- RevenueUSD 22.97B
- Net incomeUSD 7.10B
- Free cash flowUSD 4.48B
- Gross margin85.8%
Valuation Snapshot
Bullrun's latest valuation model marks Lilly(Eli) & Company as 18.9% overvalued; latest market cap is USD 1.16T; P/E is 41.9; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 41.92x versus a Healthcare sector median of 24.46x (71.4% above).
Latest dividend yield is 0.57% versus a Healthcare sector median of 2.11% (73.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 65.18B | USD 20.64B | USD 5.96B | 83.0% | 22.95 | USD 7.27B | USD 42.50B | USD 26.54B |
| FY2024 | USD 45.04B | USD 10.59B | USD 414.30M | 81.3% | 11.71 | USD 3.27B | USD 33.64B | USD 14.27B |
| FY2023 | USD 34.12B | USD 5.24B | n/a | 79.2% | 5.8 | USD 2.82B | USD 25.23B | USD 10.77B |
| FY2022 | USD 28.54B | USD 6.24B | n/a | 76.8% | 6.9 | USD 2.07B | USD 16.24B | USD 10.65B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.16T | 41.9 | 0.5% | 6.69 |
| 2025 | 2025-12-31 | USD 961.62B | 47.6 | 0.6% | 6 |
| 2024 | 2024-12-31 | USD 692.90B | 67.2 | 0.7% | 5.2 |
| 2023 | 2023-12-29 | USD 553.37B | 107.5 | 0.8% | 4.52 |
| 2022 | 2022-12-30 | USD 347.61B | 54.9 | 1.1% | 3.92 |
| 2021 | 2021-12-31 | USD 263.42B | 45.1 | 1.2% | 3.4 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 6.69 USD, yield 0.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 6.23 USD |
| FY2024 | 5.4 USD |
| FY2023 | 4.69 USD |
| FY2022 | 4.07 USD |
About Lilly(Eli) & Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Lilly(Eli) & Company overvalued or undervalued?
Bullrun's valuation model currently marks Lilly(Eli) & Company as 18.9% overvalued.
What is Lilly(Eli) & Company's market cap?
Lilly(Eli) & Company's market capitalization is USD 1.16T.
What is Lilly(Eli) & Company's P/E ratio?
Lilly(Eli) & Company's price-to-earnings (P/E) ratio is 41.9.
Does Lilly(Eli) & Company pay a dividend?
Lilly(Eli) & Company has a dividend yield of 0.6%.
What does Lilly(Eli) & Company do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.